Plus Therapeutics

Plus Therapeutics Plus Therapeutics (Nasdaq: PSTV) is a U.S. The ongoing and planned U.S.

clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers such as recurrent GBM and leptomeningeal metastases. ReSPECT Clinical Trials are evaluating 186RNL as a treatment for patients with:
- Recurrent Glioblastoma (GBM)
- Leptomeningeal Metastases (LM)
- Pediatric Brain Cancer: high grade glioma and ependymoma

announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologi...
06/05/2026

announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program, recognized as the “gold standard” in laboratory accreditation.

As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, safety programs, and overall laboratory management. now joins more than 8,000 CAP-accredited laboratories worldwide.

Full press release here: bit.ly/4o5d4Um

CNSide Diagnostics is exhibiting at Best of American Society of Clinical Oncology in Austin, Texas later this month. Thi...
06/03/2026

CNSide Diagnostics is exhibiting at Best of American Society of Clinical Oncology in Austin, Texas later this month. This event is a a free opportunity designed for clinicians, researchers, and allied health professionals seeking the latest updates in cancer care.

If you are attending, we invite you to stop by the booth to connect with our team and learn how our diagnostic platform supports precision .

Read more about the event and register: https://bit.ly/3QjzxAD

As comes to a close, our Plus Therapeutics and CNSide Diagnostics teams wore gray to honor brain cancer patients, thei...
05/28/2026

As comes to a close, our Plus Therapeutics and CNSide Diagnostics teams wore gray to honor brain cancer patients, their caregivers, advocates, and fellow researchers who work together every day to develop new diagnostics and treatments.

National Brain Tumor Society American Brain Tumor Association

announces the presentation of a new health economics study evaluating the economic impact of earlier detection and the...
05/26/2026

announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid assay.

The company believes that this cost-of-care analysis underscores that earlier LM diagnosis and therapeutic management enabled by reduces overall LM-related healthcare costs by approximately 40%. These savings are driven by earlier therapeutic intervention, improved treatment precision, and reduced hospitalizations.

The data were presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research 2026 Annual Meeting, where it was rewarded the Blue Ribbon Award as a top 5% presentation.

Full press release here: https://bit.ly/3RvFBGy

Link to poster: https://bit.ly/4uxKD45

About CNSide: https://bit.ly/49oPcoK

The and CNSide Diagnostics teams will be at the American Society of Clinical Oncology Annual Meeting, beginning at the...
05/21/2026

The and CNSide Diagnostics teams will be at the American Society of Clinical Oncology Annual Meeting, beginning at the end of next week.

Email us at [email protected] or [email protected] to schedule an onsite meeting.

This we’re highlighting our ongoing ReSPECT™ are advancing research for rare and difficult-to-treat CNS cancers, inc...
05/20/2026

This we’re highlighting our ongoing ReSPECT™ are advancing research for rare and difficult-to-treat CNS cancers, including , recurrent , and pediatric brain cancers.

Through targeted radiotherapeutic innovation, these trials aim to deliver precise treatment while sparing normal, healthy cells.

Learn more: www.respect-trials.com

announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver...
05/19/2026

announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver a unique ex*****on platform for CNS .

The AI ex*****on platform is designed to integrate, organize, and derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus’ CNS oncology technology programs.

Check out the full press release:

announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver...
05/19/2026

announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver a unique ex*****on platform for CNS .

The AI ex*****on platform is designed to integrate, organize, and
derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus’ CNS oncology technology programs.

Full press release here: bit.ly/4nDFyUX

announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming...
05/15/2026

announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming business highlights.

Read the full release: bit.ly/4uqcRgM

May is , an annual moment created by American Association for Cancer Research (AACR) to spread awareness of the efforts...
05/14/2026

May is , an annual moment created by American Association for Cancer Research (AACR) to spread awareness of the efforts being made across the globe to develop essential cancer treatments for patients.

The team is dedicated to tackling the unmet need of improving outcomes for patients with central nervous system cancers, and that mission revolves around .

Learn more about our ongoing work to support cancer patients: bit.ly/4dq65kb

Address

6420 Levit Green Boulevard, Suite 210
Houston, TX
77021

Telephone

+12109746900

Website

Alerts

Be the first to know and let us send you an email when Plus Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category